Physician profile
Daniel Tenorio
NPI 1275981417
$8,655.58
in general payments reported to CMS, 2019-2025
12 companies · $1,261 in 2025
The $1,261 reported for 2025 was more than what 75% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $35.22 · 2021: $111 · 2022: $157 · 2023: $22.17 · 2024: $7,069 · 2025: $1,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,000 · Travel and Lodging: $2,481 · Food and Beverage: $872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,000.00 |
| Travel and Lodging | $2,480.58 |
| Food and Beverage | $871.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,082.92 | 2024-2025 | |
| Zimmer Biomet Holdings, INC. | $902.86 | 2024 | Ribfix Blu Advantage, Advantagerib |
| Davol INC. | $159.96 | 2020-2024 | Bard 3dmax Mesh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.83 | 2022 | |
| Abbvie INC. | $122.76 | 2024 | |
| Csl Behring | $110.09 | 2024 | Kcentra |
| Kerecis Limited | $48.18 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Conmed Corporation | $33.23 | 2024 | Abc Handpieces |
| Haemonetics Corporation | $22.17 | 2023 | Teg6s Hemostasis System |
| Kci USA, INC. | $19.40 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.95 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $15.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Tenorio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.